Company
Destiny Pharma PLC
LON:DEST
Destiny Pharma PLC is an innovative, clinical-stage biotechnology company focused on the development and commercialisation of novel medicines that can prevent life-threatening infections. The company's drug development pipeline includes two late stage assets NTCD-M3, a microbiome-based biotherapeutic for the prevention of C. difficile infection (CDI) recurrence which is the leading cause of hospital acquired infection in the US, and XF-73 nasal gel, a proprietary drug targeting the prevention of post-surgical staphylococcal hospital infections including MRSA.
97 stories
Destiny Pharma's anti-infective impresses against skin superbugs
With several potential treatments for serious infections currently in development, Destiny Pharma PLC has therefore found itself in an enviable position.
Destiny Pharma partners with Sebela to take C.diffcile treatment through phase 3
C. difficile is one of the leading causes of hospital-acquired infection in the US
Destiny Pharma kicks off safety study of dermal formulation of key asset
The company has reformulated its nasal gel to treat post-operative infections into a skin application
Destiny Pharma gets reiterated 306p target price from finnCap following positive R&D update
The analysts noted that the entire meeting was focused on Destiny's late-stage assets, NTCD-M3 and XF-73, its development plans, competitive positioning, and market potential
Destiny Pharma's interims reveal the company has made good operational progress, says broker
finnCap tweaked its forecasts in the wake of the numbers
Archive
Small Cap Feast - accesso Technology, Destiny Pharma, Thor Mining, and more...
07 September 2022*A corporate client of Hybridan LLP** Arranged by most recent first*** Alphabetically arrangedDish of the dayJoiners:No joiners today.Leavers:Stanley Gibbons Group has left AIM. What’s cooking in the IPO kitchen?
Destiny Pharma hails positive feedback from European regulator for C. difficile phase III trial
The European Medicines Agency has said a single, final-stage study will be enough to make a marketing authorisation application
Destiny Pharma close to delivering partnership for phase III asset
The company provided an update in an overview briefing of its progress to date
Destiny Pharma hails study that underlines safety of lead asset
The biotech is making final preparations to take NTCD-M3, a new antibiotic treatment for CDI, into phase III clinical trials
Destiny Pharma to trial nasal antibiotic in breast surgery after 'positive' FDA feedback
"If this compound is successful, it would be a game changer and revolutionise the safety of breast reconstruction surgery" Alexander F Mericli, Associate Professor of Plastic Surgery at The University of Texas MD Anderson Cancer Center, sai
Destiny Pharma agrees research pact with Cystic Fibrosis Foundation
The company will assess the potential use of its XF-73 drug in treating people with cystic fibrosis that have contracted methicillin-resistant MRSA
Destiny Pharma’s XF-73 can enhance two widely used antibiotics, new research suggests
XF-73 improved the performance against MRSA and Pseudomonas aeruginosa
Destiny Pharma starts research into preventive drug for cancer treatment side effect
The research on the medication, called XF-73, will be conducted in the US by Professor Stephen Sonis
Archive
Small Cap Feast - Destiny Pharma, Poolbeg Pharma, and more...
12 May 2022*A corporate client of Hybridan LLPDish of the dayJoiners:No Joiners Today.Leavers:No Leavers Today.What’s cooking in the IPO kitchen?Trade journal, the drinks business, reports that two drinks companies of vastly different sizes
Destiny Pharma names Yuri Martina as new chief medical officer
Recently, Martina was senior vice president and deputy chief medical officer at Grunenthal Group
Destiny Pharma undervalued compared to peers, suggests finnCap
"Phase 3 trial design is due to be finalised in H1 2022, which should catalyse partnering discussions.“
Destiny Pharma expects to make significant progress with late-stage assets
The update was provided alongside the company's full-year results
Destiny Pharma raises £6.45mln for pipeline development
The biotech firm said 12.9mln new shares are set to trade on AIM
Destiny Pharma's lead assets have the potential to generate US$1bn globally each
Destiny Pharma is currently in advanced discussions with commercial partners for both assets
Destiny Pharma raises funds to finance progress towards Phase 3 trials on its two lead assets
The board conceded that the timing of the share issue could have been better given the volatility of current markets but felt it better to bite the bullet rather than wait for a stronger market
Archive
Small Cap Wrap - Serinus Energy, Midwich, Great Western Mining and more...
Great Western Mining 0.13p £4.7m (LON:GWMO) Great Western Mining Corporation PLC, which is exploring and developing gold, silver and copper targets in Nevada, today updates shareholders on its 2022 approved drilling programme.
Destiny Pharma receives the 'positive feedback' from European regulators for phase III trial
Essentially, researchers developing the nasal gel for postoperative infection will have to hit the same end-goal as they did in phase II
Destiny Pharma reports positive results from safety study of novel dermal formulation
"We are very pleased with the encouraging data from our novel XF-73 dermal formulation which is aimed at meeting a clear clinical need in a large market where peak product sales could reach half a billion US dollars," said Destiny Pharma CE
Destiny Pharma unveils positive results for c-difficile treatment as research points to commercial potential
NTCD-M3, which researchers are readying to phase III clinical trials, was the subject to a separate preclinical study by the US Department of Veterans Affairs
Destiny Pharma: Lancet study validates clinical need to fight AMR
More than one million deaths occurred in one year due to bacterial Antimicrobial Resistance (AMR), whcih the company seeks to address with in-trial candidates.
Destiny Pharma making progress towards phase 3 trials
Preclinical work on SPOR-COV, designed to prevent coronavirus infections, is progressing as planned
Destiny Pharma shares study supporting need for XF-73 nasal gel candidate
The study explored the link between Staphylococcus aureus decolonisation and Intensive Care Units infection rates
Destiny Pharma's China partner begins programme to develop new skin infection product
Destiny will have cross-reference rights to the data and so could start a similar skin infection clinical programme in the future
Destiny Pharma to build on progress made by two key assets
The company is blazing a trail in the infection arena and reckons it has two potential blockbuster treatments on its hands
Destiny Pharma publishes more evidence of XF-73 nasal gel's effectiveness
"We are very pleased to announce this additional, positive data from the successful Phase 2b study of XF-73 as a novel drug to reduce the incidence of post-surgical infections such as MRSA."
Destiny Pharma teams up with US Department of Veterans Affairs to find 'new attributes' for next-generation medicine
NTCD-M3 is being developed to combat Clostridioides difficile infections (CDI) in the gut
Destiny Pharma to present clinical study data at infectious diseases congress
The presentation is entitled, "Repeated doses of exeporfinium chloride (XF-73) nasal gel over 24 hours significantly reduced the burden of Staphylococcus aureus nasal carriage in at-risk surgical patients"
Destiny Pharma hails G7 health ministers for highlighting "silent pandemic" of antimicrobial resistance
“We are very pleased that the G7 Health Ministers Meeting has again strongly supported investment, regulatory and commercial incentives for drug developers,” said the company's chief executive, Neil Clark
Destiny Pharma makes significant strides toward phase III evaluation of potential breakthrough C.diff treatment
CEO Neil Clark said: "We have made significant progress since closing the £10.4mln equity funding in December 2020 that enabled the NTCD-M3 acquisition.”
Archive
FTSE 100 closes in the red, Wall Street fares no better
On the plus side, we've got this far without rehashing the old Star Wars "May the fourth" joke ... d'oh!
Destiny Pharma sits on cash pile as it focuses on two lead assets
The firm said it has “a great opportunity” as a UK biotechnology company focused on infection prevention
Destiny Pharma says anti-infection gel trial results 'exceptionally high'
The candidate achieved a 99.5% reduction in S. aureus bacterial nasal carriage, which the company said is a very effective reduction by accepted clinical measures
Destiny Pharma receives support from US government to develop ground-breaking wound infection treatment
The drug developer is teaming up with the National Institute of Allergy and Infectious Diseases
Destiny Pharma chief scientific officer to join COVID taskforce
Dr Bill Love will advise on the ‘delivery’ of research and innovation funding
Destiny Pharma lands Brazilian patent for post-surgical nasal gel; expects to share phase IIb results at the end of next month
The Brazilian authorities have issued what is known as a notice of allowance pending full approval next month
Destiny Pharma appoints C. difficile expert to its scientific advisory board
Professor Mark Wilcox is Head of R&D in Microbiology at the Leeds Teaching Hospitals
Destiny Pharma has announced the appointment of Dr Stephanie Bewick as its chief business officer
Most recently, Bewick was vice president, Business Development at Summit Therapeutics, a NASDAQ-listed infectious disease company, leading the out-licensing and in-licensing activities, pipeline positioning and technology valuation
Destiny Pharma completes enrolment for XF-73 trial on schedule
XF-73 has been awarded both qualifying infectious disease product and Fast Track status by the US Food and Drug Administration
Destiny Pharma starts preparations for its phase III trial of C. difficile drug; makes key appointment
The group has also brought on board high-level expertise in the form of Professor Dale Gerding, who has joined the drug developer’s scientific advisory board as well as becoming a “key consultant”
Destiny Pharma inks collaboration agreement with SporeGen for COVID-19 preventive nasal spray
The pair received an £800,000 grant from Innovate UK to fund the majority of the £1mln preclinical programme
Archive
Dechra Pharma at the giddy-up after solid start to the new fiscal year
A look at some of the major movers in London on Monday
Investments and investor services
FTSE 100 closes in the red as Brexit and trade war fears continue to hit sentiments
The International Monetary Fund issued a warning, saying a "no-deal" Brexit would send the British economy into severe shock
Archive
Sumo no heavyweight but finals should show good development, yet unlikely to divert from Brexit
The Day Ahead will continue to be dominated by the Brexit saga, with the corporate news diary limited to small cap firms, including City Pubs Group, Destiny Pharma
Archive
Retailers Tesco and ASOS to provide the main corporate excitement in coming week
Also on the retail front, WH Smith and Dunelm will issue updates as well in the Week Ahead, while on the macro front an ECB rate decision and US FOMC meeting minutes are also due
Investments and investor services
FTSE 100 closes near flat as traders sit on hands ahead of Fed
The UK blue-chip index closed nearly four points higher at 7,511
Archive
Expected US interest rate hike to draw the attention Wednesday, as Trump trade wars rumble on
Aside from the US interest rate decision, corporate updates are due from online fashion retailer Boohoo Group, outsourcer MITIE, and automotive services firm The AA ...
Archive
US interest rate hike eyed, as retailers, tour operators and utilities provide updates in coming week
Aside from the latest Federal Reserve policy meeting, the week ahead will bring updates from the likes of Next, Thomas Cook, TUI, United Utilities, and Pennon
Investments and investor services
FTSE 100 closes near flat as Middle East tensions cool
The UK blue-chip benchmark closed 1.20 points, or 0.02% at 7,258..
Archive
Travel sales set to dominate at WH Smith once again on Thursday; Hays and Saga also due up
It looks like it will be the same old story for WH Smith, with sales flying in travel but challenges remaining in its high street stores
Archive
Retailers and recruiters in focus as Tesco, ASOS, Hays and PageGroup report
The week ahead includes full-year results from Tesco and Saga, interims from ASOS, WH Smith and McCarthy & Stone, and trading updates from Robert Walters, Hays and PageGroup
Antibiotic developer Destiny Pharma rockets as Chinese partner invests £3mln at hefty premium
The money will be used for a Phase IIb clinical trial of its lead programme XF-73
TI Fluid Systems revives IPO plans in latest show of confidence in markets
Several companies have either joined the London market or announced they are going to over the past six weeks or so
Destiny Pharma believes it has the answer to superbug threat
The urgency and size of the market offers huge potential for any company that can come up with a new way to treat infections safely
FTSE 100 steadily extends gains
There has been no news flow from FTSE 100 companies to speak of today
Archive
Hotel Chocolat feeling the heat; Boohoo.com tipped to produce the goods once again
It's not been a sweet run for Hotel Chocolat shares recently, investors will be looking to see if the chocolatier's outlook can change that on Wednesday...
Archive
Focus on tour operators TUI and Thomas Cook and utilities in week ahead
Week ahead includes trading updates from tour operators TUI AG and Thomas Cook Group PLC, and numbers from Pennon Group PLC and United Utilities PLC
New float Destiny Pharma's shares race to a 30% debut premium
The company, only the second biotech float this year, is bringing through a next-generation antibiotic